


Ligandrol

Cat. No.:	HY-13981		
CAS No.:	1165910-22-4		
Molecular Formula:	C ₁₄ H ₁₂ F ₆ N ₂ O		
Molecular Weight:	338.25		
Target:	Androgen Receptor		
Pathway:	Vitamin D Related/Nuclear Receptor		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 100 mg/mL (295.64 mM)
 * "≥" means soluble, but saturation unknown.

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		2.9564 mL	14.7820 mL	29.5639 mL
	5 mM		0.5913 mL	2.9564 mL	5.9128 mL
	10 mM		0.2956 mL	1.4782 mL	2.9564 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
 Solubility: ≥ 2.5 mg/mL (7.39 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
 Solubility: ≥ 2.5 mg/mL (7.39 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
 Solubility: ≥ 2.5 mg/mL (7.39 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Ligandrol (LGD-4033) is a novel nonsteroidal, oral SARM that binds to androgen receptor with high affinity (K_i of 1 nM) and selectivity. IC₅₀ value: 1 nM (K_i, for androgen receptor) Target: androgen receptor in vitro: Ligandrol (LGD-4033), a novel nonsteroidal oral, selective androgen receptor modulator, binds androgen receptor with high affinity and selectivity. in vivo: Ligandrol (LGD-4033) has demonstrated anabolic activity in the muscle, anti-resorptive and anabolic activity in bone, and robust selectivity for muscle versus prostate in animal models. Ligandrol (LGD-4033) is well tolerated, has a long elimination half-life and dose-proportional accumulation upon multiple dosing. Ligandrol (LGD-4033) is safe, has favorable

pharmacokinetic profile, and increases lean body mass even during this short period without change in prostate-specific antigen.

CUSTOMER VALIDATION

- Drug Test Anal. 2020 Aug 27.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Basaria S, et al. The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men. J Gerontol A Biol Sci Med Sci. 2013 Jan;68(1):87-95.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA